"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

• Status: Not yet recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective interventional trial for 9 months will be carried out on 300 type-2 diabetes mellitus volunteer patients who are above 18-year-old and participants will be selected through consecutive sampling and will be evaluated on the basis of glycemic index and history of patients. Selected parameters will be measured at baseline and after the 12 weeks of therapy. Statistical analysis will be carried out by SPSS, ANOVA, and t-test.

From this experimental design, we are expecting improvement in the management of glycemic index, reduction in systolic and diastolic blood pressure, and reduction in weight GLP-1 naive patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aga Khan University
• Collaborator: Rehman Medical Institute - RMI

Criteria

Inclusion Criteria:

• Both male and female Type 2 Diabetic patients with age ≥18 years.

• Patients with HbA1c ≥ 7.5 % - ≤ 10.0%

• Patients with BMI ≥ 30

Exclusion Criteria:

• Patients with Type 1 Diabetes Mellitus

• Patients with Gestational Diabetes Mellitus.

• Patients with Chronic Renal Failure with eGFR of ≤ 30ml/min

• Patient already on another GLP 1 analogue

• The patient stopped any GLP1 analogue treatment less than 3 months back.

• Patients with history of chronic pancreatitis or pancreatic cancer.